Neurotoxicity of taxanes: Symptoms and quality of life assessment
- 1 January 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer
- Vol. 11 (1), 92-99
- https://doi.org/10.1007/bf02968010
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancerAnnals of Oncology, 2001
- Phantom Limb Pain as a Manifestation of Paclitaxel NeurotoxicityMayo Clinic Proceedings, 2000
- Managing the Neurotoxicity of Paclitaxel (Taxol®) and Docetaxel (Taxotere®) with Neurotrophic FactorsCancer Investigation, 2000
- A phase I–II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancerAnnals of Oncology, 1998
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- The TaxoidsDrugs, 1998
- Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients.Neurological Sciences, 1997
- Motor neuropathy due to docetaxel and paclitaxelNeurology, 1996
- Paclitaxel (Taxol) induces cumulative mild neurotoxicityEuropean Journal of Cancer, 1994